drugset / Trial / NCT00213512

Effect of Anti CD20 in Pemphigus Desease

NCT00213512

Phase 2/3 Completed 22 enrolled University Hospital, Rouen
Non-randomizedSingle-groupOpen-labelHealth-services research

Summary

to treat in an open non comparative clinical study patients presenting pemphigus with corticodependance, corticoresistance and contre-indication to systemic steroids.

Timeline

Start
2003-06
Primary completion
2006-06
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 375 mg/m2

Indications